

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 12, 2022**

**NEXGEL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-41173**

(Commission File Number)

**26-4042544**

(IRS Employer  
Identification No.)

**2150 Cabot Boulevard West, Suite B  
Langhorne, Pennsylvania**

(Address of principal executive offices)

**19067**

(Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	NXGL	The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock	NXGLW	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On January 12, 2022, NexGel, Inc. (the “**Company**”) issued a press release, attached hereto as Exhibit 99.1, announcing the launch of its MEDAGEL ClearComfort Hydrogel Patch. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	<a href="#">Press release issued January 12, 2022 (furnished herewith pursuant to Item 701).</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 12, 2022

**NEXGEL, INC.**

By: /s/ Adam Levy  
Adam Levy  
Chief Executive Officer

---

**NEXGEL Announces the Launch of MEDAGEL ClearComfort Hydrogel Patch**

*- ClearComfort Patches Prevent and Treat Blisters Using Advanced Hydrogel Technology -*

**LANGHORNE, Pa. – January 12, 2022**– NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the launch of its MEDAGEL ClearComfort Hydrogel Patch. The patches - using NEXGEL’s advanced hydrogel technology - prevent and treat foot blisters by comfortably insulating the skin from friction caused by rubbing and chafing in shoes.

The dynamic MEDAGEL ClearComfort Hydrogel Patches are available in a variety of shapes, including a customizable sheet that allows consumers to cut and create a perfect fit for their specific shoe needs. These patches are ideal for high-end footwear and will not leave a sticky residue on the shoe like other products. Additionally, the clear gel backing is not visible on any skin tone.

“The launch of our MEDAGEL ClearComfort Hydrogel Patches signifies our latest advancement within our MEDAGEL product portfolio, addressing an issue that affects millions of consumers around the world,” said Adam Levy, Chief Executive Officer of NEXGEL. “With multiple shapes, including those for shoe straps, heels and a customizable pad, consumers no longer have to suffer while breaking in new heels, running sneakers, or the like. Our proprietary hydrogel technology is designed to guard consumers’ skin, provide cushioning, and prevent blisters more comfortably and effectively than existing options.”

To purchase the patches, please visit [Amazon.com](https://www.amazon.com).

**About NEXGEL, INC.**

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

**Investor Contacts:**

Valter Pinto / Nick Staab  
KCSA Strategic Communications  
212.896.1254 / 212.896.1254  
[valter@kcsa.com](mailto:valter@kcsa.com) / [nstaab@kcsa.com](mailto:nstaab@kcsa.com)

**Media Contacts:**

Raquel Cona  
KCSA Strategic Communications  
212.896.1204  
[rcona@kcsa.com](mailto:rcona@kcsa.com)

---